These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11750328)

  • 1. Benefits of cyclosporine microemulsion (Neoral) C(2) monitoring are sustained at 1 year in de novo liver transplant recipients.
    Lake JR;
    Transplant Proc; 2001; 33(7-8):3092-3. PubMed ID: 11750328
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group.
    Grant D; Rochon J; Levy G
    Transplant Proc; 1996 Aug; 28(4):2232-3. PubMed ID: 8769208
    [No Abstract]   [Full Text] [Related]  

  • 3. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 4. Can three-times-a-day cyclosporine Neoral avoid cyclosporine toxicity in renal transplant recipients? A pharmacokinetic study.
    Swart N; Botha J; Tandon V; Michaels P; Pontin AR; Halkett J; Pascoe MD; Kahn D
    Transplant Proc; 2001; 33(7-8):3140-1. PubMed ID: 11750349
    [No Abstract]   [Full Text] [Related]  

  • 5. Neoral C(2) in liver transplant recipients.
    Levy GA
    Transplant Proc; 2001; 33(7-8):3089-91. PubMed ID: 11750327
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience with neoral cyclosporine through the oral route in liver transplantation.
    Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
    Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimization of cyclosporine therapy in liver transplantation.
    Pollard SG; Lodge JP
    Transplant Proc; 1998 Aug; 30(5):1816-8. PubMed ID: 9723294
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced acute rejection and side effects with neoral in liver transplantation.
    Tisone G; Vennarecci G; Pisani F; Baiocchi L; Mercadante E; Orlando G; Anselmo A; Casciani CU
    Transplant Proc; 1998 Jun; 30(4):1430-1. PubMed ID: 9636579
    [No Abstract]   [Full Text] [Related]  

  • 9. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 10. Cyclosporine versus cyclosporine microemulsion in pediatric liver transplant recipients.
    Loss GE; Brady L; Grewal HP; Siegel CT; Mead J; Bruce DS; Cronin DC; Woodle ES; Newell KA; Thistlethwaite JR; Millis JM
    Transplant Proc; 1998 Jun; 30(4):1435-6. PubMed ID: 9636581
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoral C(2) monitoring in pediatric liver transplant recipients.
    Dunn S; Falkenstein K; Cooney G
    Transplant Proc; 2001; 33(7-8):3094-5. PubMed ID: 11750329
    [No Abstract]   [Full Text] [Related]  

  • 13. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical benefit of monitoring cyclosporine C2 and C4 in long-term liver transplant recipients.
    Barakat O; Peaston R; Rai R; Talbot D; Manas D
    Transplant Proc; 2002 Aug; 34(5):1535-7. PubMed ID: 12176472
    [No Abstract]   [Full Text] [Related]  

  • 15. Uses of Neoral in pediatric liver transplantation.
    McDiarmid SV
    Transplant Proc; 1996 Aug; 28(4):2264-6. PubMed ID: 8769220
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited sampling strategy to estimate exposure to cyclosporine A in renal allograft recipients treated with Sandimmune-Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Rell K; Lao M; Wałaszewski J
    Transplant Proc; 1996 Dec; 28(6):3138-9. PubMed ID: 8962216
    [No Abstract]   [Full Text] [Related]  

  • 17. Improving the oral absorption of cyclosporine in malabsorbers: a review of the Neoral Compassionate Need Program.
    Mueller EA; Kovarik JM; Pittrow D
    Transplant Proc; 1998 Aug; 30(5):1691-3. PubMed ID: 9723246
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients.
    Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR
    Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157
    [No Abstract]   [Full Text] [Related]  

  • 19. Microemulsion cyclosporine (Neoral) immunosuppression for orthotopic liver transplantation in children reduces hospital stay.
    Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood RP
    Transplant Proc; 1998 Aug; 30(5):1848-9. PubMed ID: 9723304
    [No Abstract]   [Full Text] [Related]  

  • 20. Neoral C2 monitoring in solid organ transplantation.
    Levy GA
    Transplant Proc; 2004 Mar; 36(2 Suppl):392S-395S. PubMed ID: 15041373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.